Carisma Therapeutics (NASDAQ:CARM) & BioLineRx (NASDAQ:BLRX) Head-To-Head Comparison

BioLineRx (NASDAQ:BLRX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Valuation and Earnings

This table compares BioLineRx and Carisma Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$17.25 million	0.87	-$9.22 million	($2.41)	-1.43
Carisma Therapeutics	$10.77 million	0.19	-$60.48 million	($0.80)	-0.06

BioLineRx has higher revenue and earnings than Carisma Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for BioLineRx and Carisma Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1	0	1	1	2.67
Carisma Therapeutics	1	4	1	1	2.29

BioLineRx currently has a consensus target price of $26.00, indicating a potential upside of 655.81%. Carisma Therapeutics has a consensus target price of $1.93, indicating a potential upside of 3,910.42%. Given Carisma Therapeutics’ higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than BioLineRx.

Insider & Institutional Ownership

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares BioLineRx and Carisma Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-45.34%	-49.74%	-17.54%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Volatility & Risk

BioLineRx has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.

Summary

Carisma Therapeutics beats BioLineRx on 7 of the 13 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.